Open an account

Quoin Pharmaceuticals

QNRX · NASDAQ

$4.04−$0.28 (−6.48%)TodayMarket closed ·
Prev close $4.32

About QNRX

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The company is headquartered in Kfar Saba, Central(Hamerkaz) and currently employs 4 full-time employees. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Employees
4
Headquarters
Kfar Saba, Central(HaMerkaz)
Listed
Nov 1, 1989
Sector
Health Care
Industry
Biotechnology
Website
quoinpharma.com

QNRX key statistics

Market cap
7.99M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
48.22K
Volume
1
Open price
$4.04
High today
$4.14
Low today
$3.95
52 Week high
$23.50
52 Week low
$3.25

Quoin Pharmaceuticals (QNRX) at a glance

Quoin Pharmaceuticals (QNRX) last traded at $4.04, with a market cap of 7.99M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.95 and $4.14. The current price is 2.3% above the day's low and 2.3% below its high.

Volume so far is 1 shares, below the average of 48.22K shares a day.

Over the past year Quoin Pharmaceuticals has ranged from $3.25 to $23.50, and now sits 4% of the way up that range.

Quoin Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$1.90 per share against an estimate of -$1.64.

The average analyst price target is $22.27, 451.2% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $22.27
Low
$12.12
Now
$4.04
High
$36.75

QNRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 23.0% on average.

  1. Q3 FY24: reported -$16.45 per share against an estimate of -$17.61
  2. Q4 FY24: reported -$12.25 per share against an estimate of -$16.42
  3. Q1 FY25: reported -$6.50 per share against an estimate of -$6.19
  4. Q2 FY25: reported -$6.28 per share against an estimate of -$7.56
  5. Q3 FY25: reported -$6.71 per share against an estimate of -$5.08
  6. Q4 FY25: reported -$1.50 per share against an estimate of -$3.40
  7. Q1 FY26: reported -$1.77 per share against an estimate of -$1.97
  8. Q2 FY26: reported -$1.90 per share against an estimate of -$1.64

QNRX news

  • Avi Kapoor

    Dow Gains 100 Points; Chicago PMI Falls In August

  • Henry Khederian

    Quoin Pharmaceuticals Stock Surges Friday: What's Happening?

  • Market-Moving News for August 28th

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Avi Kapoor

    US Stocks Mixed; Sea Shares Gain After Q3 Results

  • Earnings Scheduled For November 6, 2025

Similar companies

Companies in the same industry as Quoin Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.